Shopping Cart
- Remove All
Your shopping cart is currently empty
Lucerastat(NBDGJ) is an orally available inhibitor of Glucosylceramide Synthase (GCS) with therapeutic potential for Fabry disease. GCS is a key enzyme in sphingolipid synthesis and inhibition of its activity reduces the accumulation of harmful substrates.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $599 | In Stock |
| Description | Lucerastat(NBDGJ) is an orally available inhibitor of Glucosylceramide Synthase (GCS) with therapeutic potential for Fabry disease. GCS is a key enzyme in sphingolipid synthesis and inhibition of its activity reduces the accumulation of harmful substrates. |
| Synonyms | OGT 923, NBDGJ, NB DGJ, N-(n-Butyl)deoxygalactonojirimycin, ACT 434964 |
| Molecular Weight | 219.28 |
| Formula | C10H21NO4 |
| Cas No. | 141206-42-0 |
| Smiles | C(CCC)N1[C@H](CO)[C@H](O)[C@H](O)[C@@H](O)C1 |
| Relative Density. | 1.234 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 20 mg/mL (91.21 mM), Sonication is recommended. H2O: 20 mg/mL (91.21 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO/H2O
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.